Vaccine undergoing phase 3 trial for HIV is

AIDSVAX is an experimental HIV vaccine that was developed originally at Genentech in San Francisco, California, and later tested by the VaxGen company, a Genentech offshoot. A repo published in the December 2009 New England Journal of Medicine on this Thailand clinical trial, also known as the RV144 trial, of the vaccine known as "ALVAC-AIDSVAX B/E" showed the combination treatment's efficacy ranging from 26.1 to 31.4%, which though far from optimal makes the combination AIDSVAX-Aventis vaccine one of the first impoant milestones in the world's struggle to produce a globally effective HIV vaccine. However, during the study seven paicipants were removed from the study when the results showed they had already been found with an HIV-1 infection at baseline, which changed the result from 26.1 to 31.4% vaccination efficacy. Ref: https://en.m.wikipedia.org/wiki/AIDSVAX